ReviewVaccines2022
How MALDI-TOF Mass Spectrometry Technology Contributes to Microbial Infection Control in Healthcare Settings.
Review in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 73 citations in OpenAlex.
- Article
- Benchmarking deep learning architectures for MALDI-TOF mass spectrometry in infectious disease diagnostics and vector-borne disease surveillance.NPJ digital medicine · 2026Article
- Human antibodies as emerging drugs for antimicrobial resistance.Trends in immunology · 2026Review
- A combined approach using environmental yeasts and microbial indicators to assess aquatic pollution.Environmental monitoring and assessment · 2026Article
- Membrane-Focused Strategies AgainstAntibiotics (Basel, Switzerland) · 2026Review
- Comparison of culture and culture-free methods for comprehensive identification of mycobacteria: a single-center prospective study.Journal of clinical microbiology · 2026Article
- Multidrug Resistance and Adaptive Response to Silver and Gold Nanoparticles in Methicillin-ResistantPathogens (Basel, Switzerland) · 2026Article
- Comparative evaluation of two MALDI-TOF MS systems for microbial identification: accuracy and workflow efficiency in a clinical microbiology laboratory.Microbiology spectrum · 2026Article
- Review
- Matrix-assisted laser desorption/ionization mass spectrometry (MALDI) in Alzheimer's disease: a scoping review of proteomic alterations in neurological tissues.Dementia & neuropsychologia · 2026Review
- Detection of Noncovalent Protein-Ligand Complexes of D-DT Variants by MALDI-TOF Mass Spectrometry.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Assessing the Genomic Landscape of Salmonella enterica Isolated From Cattle Faeces on a Nigerian Farm.MicrobiologyOpen · 2025Article
- Managing Candida auris in dialysis units: challenges, strategies, and future directions.International urology and nephrology · 2025Review
- Interpretable machine learning of clinical MALDI-TOF spectra discriminates carbapenem-resistantJournal of mass spectrometry and advances in the clinical lab · 2025Article
- Phenotype-First Diagnostic Framework for Tracking Fluoroquinolone Resistance inDiagnostics (Basel, Switzerland) · 2025Article
- Bacterial Proteomics and Antibiotic Resistance Identification: Is Single-Cell Analysis a Worthwhile Pursuit?Pathogens (Basel, Switzerland) · 2025Review
- A Pragmatic Strategy for Improving Diagnosis of Invasive Candidiasis in UK and Ireland ICUs.Journal of fungi (Basel, Switzerland) · 2025Article
- Comparative analysis of milk bacteria by two MALDI-MS systems.Scientific reports · 2025Article
- Preventive Immunology for Livestock and Zoonotic Infectious Diseases in the One Health Era: From Mechanistic Insights to Innovative Interventions.Veterinary sciences · 2025Review
- Microbiological diagnostics and their impact on hematology nursing.Folia microbiologica · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Healthcare settings have been utilizing matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) since 2010. MALDI-TOF MS has various benefits over the conventional method of biochemical identification, including ease of use, speed, accuracy, and low cost. This approach can solve many of the obstacles to identifying bacteria, fungi and viruses. As technology advanced, more and more databases kept track of spectra, allowing species with similar morphological, genotypic, and biochemical traits to be identified. Using MALDI-TOF MS for identification has become more accurate and quicker due to advances in sample preparation and database enrichment. Rapid sample detection and colony identification using MALDI-TOF MS have produced promising results. A key application of MALDI-TOF MS is quickly identifying highly virulent and drug-resistant diseases. Here, we present a review of the scientific literature assessing the effectiveness of MALDI-TOF MS for locating clinically relevant pathogenic bacteria, fungi, and viruses. MALDI-TOF MS is a useful strategy for locating clinical pathogens, however, it also has some drawbacks. A small number of spectra in the database and inherent similarities among organisms can make it difficult to distinguish between different species, which can result in misidentifications. The majority of the time additional testing may correct these problems, which happen very seldom. In conclusion, infectious illness diagnosis and clinical care are being revolutionized by the use of MALDI-TOF MS in the clinical microbiology laboratory.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.